Samsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides

Samsung views the deal as expanding its capabilities beyond antibodies and ADCs to include peptide therapeutics, while advancing innovation across high-growth areas such as oncology and other emerging indications.

The post Samsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides appeared first on GEN - Genetic Engineering and Biotechnology News.